STRAX: Improved Outlook
Redeye remains positive to STRAX following a solid Q2-beat, with topline growth of 27% y/y. The performance during the COVID-19 crisis has surpassed our expectations, and we believe STRAX, with a solid pipeline, is well-positioned to grasp the opportunity as the market recovers. As we previously highlighted, the strong performance justified an increased base case valuation.